[Therapy of Parkinson disease. 2: New therapy concepts for treating motor symptoms].
New approaches in Parkinsonian pharmacotherapy may be (1) inhibition of catechol-O-methyl-transferase influencing the metabolism of dopamine, (2) the use of budipine, which is assumed to be neuroprotective, with an effect especially on tremor, (3) the application of NADH with the postulated stimulation of the endogenous dopamine synthesis and (4) the revival of stereotaxic surgery with the lesion or the stimulation of certain brain areas, enabled by the development of new and more sensitive methods. Neuroprotective, and/or neuroregenerative therapeutic approaches, like e.g. application or stimulation of growth factors and/or transplantation of neuronal dopaminergic cells, may redirect Parkinsonian therapy from present palliative, symptomatic therapeutic principles to acurative therapy in the future.
Kuhn
W
W
Neurologische Klinik im St. Josef-Hospital Ruhr-Universität Bochum.
Müller
T
T
D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016380:Brain Tissue Transplantation; D005544:Forecasting; D006801:Humans; D009460:Neurologic Examination / Q000187:drug effects; D018696:Neuroprotective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000209:etiology / Q000628:therapy*; D013238:Stereotaxic Techniques
D000978:Antiparkinson Agents; D018696:Neuroprotective Agents